表紙
市場調査レポート

世界のオピオイド市場:薬物乱用防止用ブランドジェネリックへの集中度の増加が、従来は分散化されていた市場の競争動向を変える

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

発行 GBI Research 商品コード 200292
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界のオピオイド市場:薬物乱用防止用ブランドジェネリックへの集中度の増加が、従来は分散化されていた市場の競争動向を変える Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market
出版日: 2013年01月04日 ページ情報: 英文 43 Pages
概要

現在のオピオイドの世界市場は、製品構造が高度に多様化・細分化されており、また内部の競争が非常に激しいという特徴があります。ここ数年は薬物乱用に対する懸念の増大から、薬物乱用を防止するような製品へと市場がシフトしています。

当レポートでは、全世界のオピオイド市場の最新動向と将来展望について分析し、近年の市場構造・動向や課題、現在の上市製品の概要、市場促進・抑制要因、現在開発中のパイプライン製品、近年の資本取引の動きなどを調査して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • イントロダクション
    • 競争の激しい市場環境における、高いレベルの製品多様化
    • 処方薬に対する臨床医の選好の不一致
    • 薬物乱用防止製品の製剤に向けた、現在進行中の市場のシフト
    • 医師団体が、オピオイドの乱用の程度に関する懸念の声を挙げ始める
    • 経皮パッチ剤の完全商用化の可能性は、まだ十分には開拓されていない

第3章 現在市販されている製品の概要

  • 主な市販製品
    • Oxycontin
    • Exalgo
    • Onsolis
    • Duragesic
    • Opana ER
    • Vicodin CR
    • Dolophine Hydrochloride
    • Oxecta
    • Actiq
    • Embeda
    • Kadian
    • Avinza
  • 市場促進・抑制要因
    • 市場促進要因
    • 市場抑制要因

第4章 パイプライン分析

  • イントロダクション
  • 開発パイプライン上のオピオイド化合物
  • 投薬経路別の内訳
  • 有望なパイプライン製品
    • ARX-01(AcelRX Pharmaceuticals)
    • ALO-02(Pfizer)
    • Zohydro ER(Zogenix)
    • ELI-216(Elite Pharmaceuticals)
    • BEMA Buprenorphine
    • CEP-33237(Cephalon)

第5章 資本取引分析

  • 概要
    • 企業合併・買収(M&A)の年間件数
    • M&Aの金額別内訳
    • 主なM&A
  • ライセンス契約
    • ライセンス契約の年間件数
    • ライセンス契約の金額別内訳
    • 主なライセンス契約
  • 共同開発契約
    • 契約件数の推移
    • 主な共同開発契約

第6章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC252MR

Summary

Leading business intelligence provider GBI Research has released its latest research report, entitled "Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market". The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics. As a result, most patient populations experiencing more severe levels of pain across most pain indications, with the exception of, for example, migraines, are heavily dominated by opioids. As a therapeutic drug class, opioids have virtually no competition from molecules with non-opioid receptor targets. However, although the competition is virtually exclusively limited to opioid compounds, the current environment within this therapeutic class is highly competitive and strongly diversified. The approved drugs are based on 16 different opioid compounds and are differentiated on a range of characteristics, which include dosage, route of administration and pharmacokinetic features, as well as increasingly on the basis of abuse-resistance technologies.

Whilst the prescription rates of opioid analgesic have seen a historically unprecedented increase over the last two decades, particularly in the US, this has resulted in a dramatic concomitant increase in opioid abuse and dependency. Over the last few years, the growing concern over opioid abuse has resulted in tighter regulations and increasingly vocal concerns by physicians. Due to these concerns from regulatory authorities and physicians about growing opioid abuse, there has been a seismic shift towards developing abuse-resistant formulations of extended-release opioid analgesics, including both novel products and reformulations of existing ones. Since the launch of the first abuse-resistant product, Embeda, in 2009, a whole range of novel products and reformulations of existing product ranges have been brought to the market. While abuse-resistant formulations do not confer any clinical benefits, they have become an essential differentiating factor in the current market environment in order ensure that products remain competitive for the future. There is a growing concentration and competition among abuse-resistant products, which is expected to be the primary driving factor in this largely stagnant market, particularly as the current developmental pipeline is very small and is characterized by a lack of innovation, with virtually no novel compounds and strong saturation across multiple pain indications.

Scope

  • An overview of the current opioid product market.
  • A brief discussion about the inconsistent prescription preferences among European physicians.
  • A brief profile of the most important opioid products.
  • A pipeline analysis of the opioid products currently in development and an overview of the developmental pipeline by phase, by the route of administration and a summary of the promising pipeline products.
  • An overview of the M&A and licensing deals, as well as co-development deals, across multiple indications in which opioids are frequently used in patients suffering from moderate to severe pain.

Reasons to buy

  • Identify trends in the developmental pipeline for opioid analgesics.
  • Develop their awareness of the regulatory environment, physician concerns and inconsistency of prescription preferences among physicians.

Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 6
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Introduction 7
    • 2.1.1 High Levels of Product Diversification in a Highly Competitive Market Environment 7
    • 2.1.2 Inconsistent Clinician Prescribing Preferences 7
    • 2.1.3 Ongoing Market Shift Towards Abuse-Resistant Product Formulations 8
    • 2.1.4 Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse 9
    • 2.1.5 Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited 9

3 Overview of Currently Marketed Products 10

  • 3.1 Major Marketed Products 10
    • 3.1.1 Oxycontin 10
    • 3.1.2 Exalgo 10
    • 3.1.3 Onsolis 10
    • 3.1.4 Duragesic 11
    • 3.1.5 Opana ER 11
    • 3.1.6 Vicodin CR 11
    • 3.1.7 Dolophine Hydrochloride 11
    • 3.1.8 Oxecta 11
    • 3.1.9 Actiq 12
    • 3.1.10 Embeda 12
    • 3.1.11 Kadian 12
    • 3.1.12 Avinza 12
  • 3.2 Market Drivers and Barriers 13
    • 3.2.1 Drivers 14
    • 3.2.2 Barriers 15

4 Pipeline Analysis 17

  • 4.1 Introduction 17
  • 4.2 Opioid Compounds in the Developmental Pipeline 20
  • 4.3 Distribution by Route of Administration 23
  • 4.4 Promising Pipeline Products 26
    • 4.4.1 ARX-01, AcelRX Pharmaceuticals 26
    • 4.4.2 ALO-02, Pfizer 26
    • 4.4.3 Zohydro ER, Zogenix 26
    • 4.4.4 ELI-216, Elite Pharmaceuticals 27
    • 4.4.5 BEMA Buprenorphine 27
    • 4.4.6 CEP-33237, Cephalon 27

5 Deals Analysis 28

  • 5.1 Overview: 28
    • 5.1.1 M&As by Year 28
    • 5.1.2 M&As by Value 29
    • 5.1.3 Major M&As 30
  • 5.2 Licensing Agreements 33
    • 5.2.1 Licensing Agreements by Year 33
    • 5.2.2 Licensing Agreements by Value 34
    • 5.2.3 Major Licensing Agreements 35
  • 5.3 Co-Development Agreements 38
    • 5.3.1 Deals by Year 38
    • 5.3.2 Major Co-Development Deals 39

6 Appendix 40

  • 6.1 Abbreviations 40
  • 6.2 Bibliography 41
  • 6.3 Research Methodology 41
    • 6.3.1 Coverage 41
    • 6.3.2 Secondary Research 42
    • 6.3.3 Primary Research 42
    • 6.3.4 Pipeline Analysis 42
    • 6.3.5 Expert Panel Validation 42
  • 6.4 Contact Us 43
  • 6.5 Disclaimer 43

List of Tables

  • Table 1: Opioids Market, Global, R&D Pipeline Analysis by Phase, 2012 18

List of Figures

  • Figure 1: Opioids Market, Drivers and Barriers, 2012 13
  • Figure 2: Opioids Market, Global, R&D Pipeline by Phase (%), 2012 17
  • Figure 3: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase III 20
  • Figure 4: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase II 21
  • Figure 5: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase I 22
  • Figure 6: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase III 23
  • Figure 7: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase II 24
  • Figure 8: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase I 25
  • Figure 9: Opioids Market, M&As by Year, 2005-2012 28
  • Figure 10: Opioids Market, M&As by Value ($m), 2005-2012 29
  • Figure 11: Opioids Market, Licensing Agreements by Year, 2005-2012 33
  • Figure 12: Opioids Market, Licensing Agreements by Value ($m), 2005-2012 34
  • Figure 13: Opioids Market, Co-Development Agreements by Year, 2005-2012 38
Back to Top